7081 research outputs found
Sort by
Creating a Robust Learning Experience for RN Residents: Activating RRTs Using Multimodal Learning
No full textSafety, Efficacy, and Adjacent-level Fracture Risk Following Vertebral Augmentation and Radiofrequency Ablation for the Treatment of Spine Metastases in Patients with Cancer
No full textPurpose To evaluate the safety and efficacy of vertebral augmentation (VA) and radiofrequency ablation (RFA) for treating pathologic spinal fractures in patients with cancer and adjacent fracture risk following treatment. Materials and Methods This single-institution retrospective study, conducted from January 2017 to September 2020, included patients with cancer who underwent percutaneous VA with or without spine RFA for pathologic spine compression fractures. The primary outcome was pain reduction, assessed using the 10-point visual analog scale before the procedure, at first follow-up, and 2-4 weeks after the procedure. Logistic regression was performed to identify factors associated with epidural cement leak. Results A total of 638 spinal levels in 335 patients (median age, 65 years [IQR, 58-74 years]; 147 female, 188 male) were treated. Epidural tumor and retropulsion of bone fragments were present in 15% (93 of 638) and 13% (81 of 638) of treated levels, respectively, while posterior wall erosion was observed in 30% (190 of 638). Substantial pain improvement (greater than two-point reduction) occurred in 81% (519 of 638) of cases. Factors associated with decreased risk of epidural cement leak included RFA (42% no leak vs 38% leak, P = .03) and lumbar treatments (49% no leak vs 38% leak, P = .02). Adjacent-level fractures occurred in 10.4% of patients. The total complication rate (National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or higher) was 0.6% (four of 638). Conclusion VA and RFA are safe and efficacious treatments for spine fractures in patients with cancer
Gabapentinoids confer survival benefit in human glioblastoma
No full textNeuronal-glioma interactions are increasingly recognized as critical in the development and progression of central nervous system tumors. Recent research highlights that gliomas can integrate into neural circuits through various mechanisms, including the synaptogenic factor thrombospondin-1 (TSP-1). This new mechanistic understanding of cancer neuroscience allows for novel insights into target discovery. Critically, therapies that modulate neuron-tumor interactions remain agnostic to other oncogenic changes within tumor cells yet may still target fundamental drivers of tumor growth. In line with these findings and controlling for critical confounding variables, we demonstrate a survival benefit associated with gabapentin (an antagonist of TSP-1) following surgical resection of newly diagnosed glioblastoma. This retrospective, multi-institutional cohort study included 1,072 patients, with a discovery cohort of 693 patients and an additional 379 patients from a separate site for external validation. Furthermore, our findings indicate that gabapentin administration is associated with reduced serum TSP-1 levels, suggesting its potential as a future biomarker
Igniting the Spark: EBP for Novice Nurses
No full texthttps://scholarlycommons.baptisthealth.net/bhsf-academic-week-2025/1021/thumbnail.jp
Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial
No full textSocial Determinants of Health in Thoracic Surgery: Critical Points for Understanding and Implementing Change
No full textImproving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
No full text
